The concurrent administration of drugs that are potent OATP inhibitors, such as rifampicin [2] and cyclosporine A (CsA) [3,4], has been reported to increase systemic exposure of OATP substrates such as statins and is associated with statin-induced myopathy [5,6]. Here, SLCO1A2 is linked to myopathy.